Nonalcoholic steatohepatitis (NASH)

NN9500-4656 study

Do you have NASH?

Consider participating in the NN9500-4656 study evaluating three investigational drugs for their ability to treat Non-Alcoholic Steatohepatitis (NASH).

Join NN9500-4656 for up to 19 months of expert care where your health is in focus.

Inventiva 337HNAS20011 Study

The NATiV3 Study is a clinical study evaluating an investigational drug as a potential treatment for people living with NASH. The investigational drug will potentially target 3 peroxisome proliferator-activated receptors which could lead to an increase in the ability of the body to regulate insulin, inflammation, and improve scarring of the liver caused by NASH.